Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 07, 2020
Notification of investor briefing webinar
Dec 07, 2020
Positive opinion for all 3 Orphan applications in Europe
Nov 19, 2020
Approval received for final stage of NNZ-2591 clinical trial
Oct 29, 2020
Quarterly report and cash flow statement for Q3 2020
Sep 29, 2020
Neuren requests Orphan designations for NNZ-2591 in Europe
Sep 22, 2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
Aug 26, 2020
Half-year Shareholder Update
Aug 26, 2020
Half Yearly Report and Accounts
Aug 18, 2020
Corporate presentation, 18 August 2020
Aug 11, 2020
Change of Director's Interest Notice
1
2
3
4
5
6
Next
